Exploration and Evaluation of Therapeutic Efficacy of Drug‐Free Macromolecular Therapeutics in Collagen‐Induced Rheumatoid Arthritis Mouse Model

Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine

(2019) Jiawei Wang et al.   Nanomedicine-Nanotechnology Biology and Medicine

The B side of Rheumatoid Arthritis pathogenesis

(2019) Stefano Alivernini et al.   PHARMACOLOGICAL RESEARCH

Broadening and Enhancing Functions of Antibodies by Self-Assembling Multimerization at Cell Surface

(2019) Lian Li et al.   ACS Nano

B cell targeted therapies in autoimmune disease

(2019) Jennifer L Barnas et al.   CURRENT OPINION IN IMMUNOLOGY

Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics

(2018) Lian Li et al.   ACS Nano

First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils

(2018) Felix Weber et al.   PHARMACEUTICAL RESEARCH

Biorecognition: A key to drug-free macromolecular therapeutics

(2018) Jiyuan Yang et al.   BIOMATERIALS

Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs

(2018) Lian Li et al.   JOURNAL OF CONTROLLED RELEASE

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

(2017) Venkat Reddy et al.   RHEUMATOLOGY

A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

(2016) Narges Seyfizadeh et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Micro-CT evaluation of rheumatoid arthritis mouse model disease progression: Manual tracings versus semi-automated routines

(2016) A.C. Antill et al.   Diagnostic and Interventional Imaging

The pathogenic role of angiogenesis in rheumatoid arthritis

(2015) Hatem A. Elshabrawy et al.   ANGIOGENESIS

The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model

(2015) Lingdong Quan et al.   PHARMACEUTICAL RESEARCH

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

(2015) Te-Wei Chu et al.   Theranostics

Drug-free macromolecular therapeutics – a new paradigm in polymeric nanomedicines

(2015) Te-Wei Chu et al.   Biomaterials Science

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

(2015) Venkat Reddy et al.   Arthritis & Rheumatology

B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis

(2014) Hilke Brühl et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

B Cell Depletion Inhibits Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice

(2014) S. Yu et al.   JOURNAL OF IMMUNOLOGY

Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4+ T Cell Reactivity

(2014) K. Hamel et al.   JOURNAL OF IMMUNOLOGY

Nanomedicines for Inflammatory Arthritis: Head-to-Head Comparison of Glucocorticoid-Containing Polymers, Micelles, and Liposomes

(2013) Lingdong Quan et al.   ACS Nano

Cell Surface Self-Assembly of Hybrid Nanoconjugates via Oligonucleotide Hybridization Induces Apoptosis

(2013) Te-Wei Chu et al.   ACS Nano

Quantification of bone changes in a collagen-induced arthritis mouse model by reconstructed three dimensional micro-CT

(2013) Shu Yang et al.   BIOLOGICAL PROCEDURES ONLINE

A rheumatoid factor paradox: inhibition of rituximab effector function

(2013) Jonathan D Jones et al.   ARTHRITIS RESEARCH & THERAPY

Development of macromolecular prodrug for rheumatoid arthritis

(2012) Fang Yuan et al.   ADVANCED DRUG DELIVERY REVIEWS

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

(2012) Marcin Okroj et al.   CANCER TREATMENT REVIEWS

Erosions versus joint space narrowing in rheumatoid arthritis: what do we know?

(2011) D. van der Heijde   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

(2011) P. Engel et al.   PHARMACOLOGICAL REVIEWS

PML problems loom for Rituxan

(2010) Malorye Allison   NATURE BIOTECHNOLOGY

New therapies, new concerns: rituximab-associated lung injury

(2010) Larry C. Lands   PEDIATRIC NEPHROLOGY

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Rituximab: A new therapeutic alternative in rheumatoid arthritis

(2008) Jean Sibilia et al.   JOINT BONE SPINE